Failure to maintain long-term adherence to highly active antiretroviral therapy:: the role of lipodystrophy
Failure to maintain long-term adherence to highly active antiretroviral therapy:: the role of lipodystrophy
复制标题
DOI：
10.1097/00002030-200112070-00012
复制
发表时间：
2001-12-07
期刊：
影响因子：
3.8
通讯作者：
Leport, C
中科院分区：
文献类型：
--
作者：
Duran, S;Savès, M;Leport, C
在法国APROCO队列研究中纳入的277例患者样本中，这些患者在开始含蛋白酶底物方案后4个月的随访访视时最初依从，76.4%的患者自报至少一种脂肪代谢障碍相关症状，30.0%的患者在入组后20个月未能维持依从行为。在对其他相关因素进行多重调整后，如年龄较小，饮酒和住房条件差，自我报告的脂肪代谢障碍症状的数量与依从性失败独立相关。(C)2001年利平科特威廉姆斯&威尔金斯。
In a sample of 277 patients included in the French APROCO cohort study who were initially adherent at follow-up visit 4 months after initiation of a protease inhibitor-containing regimen, 76.4% self-reported at least one lipodystrophy-related symptom and 30.0% failed to maintain adherence behaviour 20 months after enrolment. After multiple adjustment for other related factors, such as younger age, alcohol consumption and poor housing conditions, the number of self-reported lipodystrophy symptoms was independently associated with adherence failure. (C) 2001 Lippincott Williams & Wilkins.